Evolution of the Average Target: Forte Biosciences, Inc.

Evolution of the Target Price: Forte Biosciences, Inc.

Changes in Analyst Recommendations: Forte Biosciences, Inc.

c5338e8df323.6-V5fmt7YgNsndLnph5ZhfayKm1yxVhCol-ukKlb93s.vZFIT0YqMHtB-ojW1Cpo9JGBYQEAgz4w92uc8sArnxKFljw_BCoETQqp5g~878ff20faa758b3c14012e43dee47576
07-27 Global markets live: Nvidia, Coca-Cola, Rocket Lab, KKR, OpenAI… Zonebourse
07-21 Barclays Initiates Forte Biosciences at Overweight With $74 Price Target MT
07-09 Top Midday Gainers MT
25-10-03 Forte Biosciences reports inducement grants under Nasdaq listing rules RE
25-08-18 Guggenheim Initiates Coverage on Forte Biosciences With Buy Rating, $75 Price Target MT
25-04-02 Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating MT
25-01-21 TD Cowen Initiates Forte Biosciences at Buy MT
24-11-15 Chardan Boosts Price Target on Forte Biosciences to $64 From $3, Keeps Buy Rating MT
24-05-30 Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target MT
21-09-20 Forte Biosciences : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4 MT
21-09-07 Forte Biosciences : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy MT
21-09-07 Forte Biosciences : Brookline Capital Downgrades Forte Biosciences to Hold from Buy MT
21-09-03 Forte Biosciences : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket MT
21-09-03 Forte Biosciences : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy MT
21-09-03 Forte Biosciences : B. Riley Downgrades Forte Biosciences to Neutral from Buy After Lead Program FB-401 Failed to Strike Primary Endpoint, Lowers PT to $3 from $73 MT
21-09-03 Forte Biosciences : Truist Securities Downgrades Forte Biosciences to Hold from Buy MT
21-05-14 Forte Biosciences : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis MT
21-03-26 Forte Biosciences : Citigroup Starts Forte Biosciences at Buy With $75 Price Target MT
21-03-17 Forte Biosciences : Chardan Capital Adjusts Price Target on Forte Biosciences to $105 From $115, Maintains Buy Rating MT
20-11-11 Forte Biosciences : Chardan Adjusts Forte Biosciences' Price Target to $115 From $110, Keeps at Buy MT
20-08-25 Forte Biosciences : Shares Higher After Truist Initiates Coverage DJ

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-5.18%
+14.99%
- +6.36%
+8.86%
+64.91%
+9.22%
-13.98%
+11.23%
+17.17%
-4.09%
Average +10.95%
Weighted average by Cap. +13.25%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
76.99USD
Average target price
73.00USD
Spread / Average Target
-5.18%
High Price Target
77.00USD
Spread / Highest target
+0.01%
Low Price Target
61.00USD
Spread / Lowest Target
-20.77%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. FBRX Stock
  4. Consensus Forte Biosciences, Inc.